trending Market Intelligence /marketintelligence/en/news-insights/trending/1hwX-YjfO5IP3ta5PbgkFQ2 content esgSubNav
In This List

Orthocell, DePuy Synthes partner for treatment of degenerate tendons, ligaments

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Orthocell, DePuy Synthes partner for treatment of degenerate tendons, ligaments

Orthocell Ltd. entered a research collaboration agreement with DePuy Synthes Products Inc., a part of the Johnson & Johnson family of companies, for its Ortho-ATI stem cell approach for the regeneration of degenerate tendons and ligaments.

A collaborative study is planned to start in the first quarter of 2017.

The treatment has shown itself to be a cost-effective and durable non-surgical solution for difficult to treat tendon injuries in studies done by Orthocell. It is available in Australia and New Zealand for patients who have failed conservative treatment options such as corticosteroid injections and exercise programs and have ongoing symptoms.

The collaboration was facilitated by Johnson & Johnson Innovation.